Hosted on MSN17d
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...
FIRDAPSE now available in Japan for muscle weakness
CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
Benzinga.com17d
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
In May, the FDA approved its supplemental New Drug Application, increasing the indicated maximum daily dose of Firdapse’s (amifampridine) for adults and pediatric patients weighing more than 45 ...
Finanznachrichten18d
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva Pharmaceuticals
This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE ® ...
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation brought by Catalyst ...